80.00 0.00 (0.00%)
After hours: 4:54PM EDT
|Bid||79.14 x 100|
|Ask||80.84 x 100|
|Day's range||79.64 - 80.60|
|52-week range||76.41 - 89.72|
|PE ratio (TTM)||39.14|
|Earnings date||24 May 2018|
|Forward dividend & yield||1.84 (2.31%)|
|1y target est||90.84|
On April 6, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings ratio) of 20.1x, while its PE was 57.6x. A lower forward estimate compared to the current PE represents analysts’ expectations that a company will generate higher earnings over the next 12 months.
The dividend will be payable on May 15, 2018, to shareholders of record on April 13, 2018. Abbott Laboratories is part of the S&P 500 Dividend Aristocrats, which are the companies that have paid out consistently increasing dividends to shareholders for at least 25 consecutive years. As of April 6, 2018, ABT stock has a dividend yield of 1.9%.
On April 5, 2018, Abbott Laboratories (ABT) ended the trading day at $59.86 per share. The stock registered a rise of ~0.67% in its stock price compared to its previous day’s close. For more details, read Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results.
Abbott Laboratories (ABT) showed an impressive performance in 2017 despite a challenging macroeconomic environment and big-ticket acquisitions. The company reported strong 2017 results on January 24, 2018, and it has secured a number of product approvals and reimbursement approvals since then, strengthening its market position.
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan. MitraClip is a minimally invasive procedure for patients suffering from MR (mitral regurgitation) who are at high risk of open surgery.
Medtronic's (MDT) latest restructuring Enterprise Excellence plan intends to achieve $3 billion of annual growth run rate savings by the end of fiscal 2022
On March 23, 2018, Edwards Lifesciences (EW) announced that it won its dispute with Boston Scientific (BSX) over US Patent 8992608. The USPTO (US Patent and Trademark Office) decided in favor of Edwards in an inter partes review filed by Boston Scientific against Edwards for its TAVR (transcatheter aortic valve replacement) technology, finding all the related claims against Edwards to be invalid.
The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands
A new article raises troubling questions about a major NIH-funded cardiology clinical trial. But instead of expressing concern, medical leaders instead focus their ire and criticism on the trial's critics. They say it is improper to attack the trial without first checking with the trial leaders.
Spinal cord stimulation isn't as scary as it sounds. Innovation in the devices and a push away from treating chronic pain with opioids are causing the market to boom.